Amide local anesthetic (intermediate-acting low-toxicity)

Plain-language summaryIntrigue 50 / 100

Prilocaine (Citanest) is an amide local anesthetic with the lowest systemic toxicity in the class, reflecting rapid hepatic clearance and high tissue redistribution. It is the partner of lidocaine in EMLA cream, where the eutectic mixture of the two oils provides effective topical anesthesia of intact skin for venipuncture and minor procedures. The defining downside: dose-dependent methemoglobinemia. Liver enzymes hydrolyze prilocaine to o-toluidine, which is hydroxylated to a metabolite that oxidizes hemoglobin iron and prevents oxygen binding. Cumulative doses above 600 mg in adults (or 8 mg/kg in children) can produce clinically significant methemoglobinemia requiring methylene blue therapy. Risk amplifies in G6PD deficiency, NADH-methemoglobin reductase deficiency, or with concurrent oxidant drugs. Widely used in European and Asian dental cartridges. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

37/100

A 1960s amide anesthetic with fully solved pharmacology and no live research frontier

Look, prilocaine is a 1960s clinical anesthetic and that’s basically the whole story. Developed at AB Astra, introduced as Citanest, now best known as the lidocaine partner in EMLA cream. The mechanism is textbook sodium channel block. The same story you’d tell for every other amide local anesthetic, just with a slightly more favorable systemic toxicity profile and a dose-dependent methemoglobinemia liability as the tradeoff.

The novelty score is essentially at floor. Voltage-gated sodium channel block has been worked out in extraordinary detail across decades of electrophysiology and structural biology. There’s nothing new here mechanistically. Prilocaine does add the o-toluidine metabolism angle, which generates methemoglobin at higher cumulative doses, and thats genuinely interesting biochemistry. But it’s 1960s biochemistry. The cytochrome-mediated hydroxylation cascade that produces the oxidant metabolite has been mapped extensively; the G6PD vulnerability is well-characterized; the methylene blue reversal story is settled. A researcher asking why prilocaine causes methemoglobinemia is asking a question with a published answer from 1972.

The lowest-systemic-toxicity claim is real. On a mg/kg basis, prilocaine shows a wider margin before CNS and cardiac toxicity than lidocaine or bupivacaine, reflecting rapid redistribution and hepatic clearance. That’s a genuine differentiator within the amide class. But this doesn’t open a research question; it’s a favorable side effect of known kinetics that is already fully incorporated into clinical practice. There’s nothing left to discover, and investigators have known this for decades.

Evidence quality is high because the compound is old. Multi-decade clinical use, well-replicated pharmacokinetics, clear EMLA cream data across multiple controlled trials. Translational signal is strong for its primary indication. But high evidence quality on a sixty-year-old mechanism is the opposite of exciting; it means the research is done. The compound is well-understood precisely because the open questions closed long ago.

Bench value is limited. If you’re studying sodium channel pharmacology, lidocaine is the canonical probe with vastly more supporting infrastructure. If you’re studying methemoglobinemia, dapsone and benzocaine are more commonly used experimental models with larger literatures. Prilocaine sits awkwardly between these niches without being optimal for either. We dont see a reason to reach for it as a tool when better-characterized probes exist on both flanks.

Honestly, the score here is low because this is solved pharmacology from six decades back. Thats not a knock on the compound clinically; it works reliably and has for sixty years. But reliable and fully understood is the description of a closed research question. Bench scientists hunting for a live research lead would look elsewhere, and we think they’d be right to.

Novelty: 12
Mechanism promise: 18
In-category differentiation: 32
Evidence quality: 72
Translational signal: 75
Research bench value: 30

Rationale Prilocaine scores near-floor on novelty and mechanism because it’s a textbook sodium channel blocker introduced in the 1960s whose only distinctive feature, methemoglobinemia via o-toluidine hydroxylation, is settled biochemistry from fifty years ago. High evidence and translational scores reflect clinical maturity rather than research opportunity, pulling the overall modestly above true floor compounds while keeping it well below anything a bench scientist would prioritize.

Amide local anesthetic (intermediate-acting, low-toxicity)

An amide local anesthetic with the lowest systemic toxicity in the class but the dose-dependent risk of methemoglobinemia from o-toluidine metabolite generation.

Abstract

Prilocaine (N-(2-methylphenyl)-2-(propylamino)propanamide; CAS 721-50-6; molecular formula C13H20N2O; molecular weight 220.31) is an amide local anesthetic developed at AB Astra in the late 1950s and introduced clinically in the 1960s (Citanest). The compound has the lowest systemic toxicity in the amide class (CNS and cardiac toxic doses higher than lidocaine, mepivacaine, or bupivacaine on a milligram-per-kilogram basis), reflecting rapid hepatic clearance and high tissue redistribution. Prilocaine is the principal component of the EMLA cream alongside lidocaine, where the eutectic mixture of the two oils provides effective topical anesthesia of intact skin for venipuncture and minor superficial procedures. The principal clinical limitation is dose-dependent methemoglobinemia: prilocaine is hydrolyzed in the liver to o-toluidine, which is hydroxylated to a methemoglobin-generating metabolite. Cumulative doses above approximately 600 mg in adults or 8 mg/kg in children produce clinically significant methemoglobinemia that may require methylene blue therapy. The risk is amplified in patients with G6PD deficiency, NADH-methemoglobin reductase deficiency, or concurrent administration of other oxidant drugs (dapsone, sulfamethoxazole, benzocaine). Mechanism is the standard amide voltage-gated sodium channel block. Onset and duration are intermediate (similar to lidocaine and mepivacaine). Prilocaine is widely used in dental anesthesia in Europe and Asia and is the principal component of dental cartridges in several markets. Maximum recommended dose is 8 mg/kg without epinephrine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1313Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Amide local anesthetic (intermediate-acting low-toxicity)

Prilocaine

Abstract

Read the full monograph